ArticleJCO precision oncology2022
Distinct Neoadjuvant Chemotherapy Response and 5-Year Outcome in Patients With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Tumors That Reclassify as Basal-Type by the 80-Gene Signature.
Article in JCO precision oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01479101 (Prospective Neo-adjuvant REGISTRY Trial Linking MammaPrint, Subtyping and Treatment Response), which is not on this map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prospective Neo-adjuvant REGISTRY Trial Linking MammaPrint, Subtyping and Treatment Response: Neoadjuvant Breast Registry - Symphony Trial (NBRST) (Pronounced "in Breast")
Who cites it
14 citing papers in PubMed, 18 citations in OpenAlex.
- Prediction of Anthracycline Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early-Stage Breast Cancer by the MammaPrint 70-Gene Signature for Patients Enrolled in the FLEX Study.JCO precision oncology · 2026Article
- Identification of racial disparities across MammaPrint and BluePrint subtypes in HR + HER2- breast cancer.NPJ breast cancer · 2026Article
- Determinants of long-term response to patritumab deruxtecan in breast cancer patient-derived xenografts.NPJ precision oncology · 2025Article
- Artificial Intelligence-Based Pathology to Assist Prediction of Neoadjuvant Therapy Responses for Breast Cancer.Cancer medicine · 2025Review
- Successful unconventional precision treatment of inflammatory hormone receptor-positive breast cancer guided by molecular profiling.NPJ precision oncology · 2025Article
- Longitudinal evaluation of circulating tumor DNA in patients undergoing neoadjuvant therapy for early breast cancer using a tumor-informed assay.Nature communications · 2025Article
- Extratumoral signs on mammography as a novel prognostic indicator for breast cancer: evidence from malignant nonspiculate and noncalcified masses.American journal of translational research · 2025Article
- Immune and gene-expression profiling in estrogen receptor low and negative early breast cancer.Journal of the National Cancer Institute · 2024Article
- Defining the Biology of Estrogen Receptor-Low-Positive Breast Cancer.Annals of surgical oncology · 2024Article
- Nodal pCR and overall survival following neoadjuvant chemotherapy for node positive ER+/Her2- breast cancer.Breast cancer research and treatment · 2024Review
- The Predictive Utility of MammaPrint and BluePrint in Identifying Patients with Locally Advanced Breast Cancer Who are Most Likely to Have Nodal Downstaging and a Pathologic Complete Response After Neoadjuvant Chemotherapy.Annals of surgical oncology · 2023Article
- Multigene profiles to guide the use of neoadjuvant chemotherapy for breast cancer: a Copenhagen Breast Cancer Genomics Study.NPJ breast cancer · 2023Article
- Genomic Classification of HER2-Positive Patients With 80-Gene and 70-Gene Signatures Identifies Diversity in Clinical Outcomes With HER2-Targeted Neoadjuvant Therapy.JCO precision oncology · 2022Article
- Transfer RNAs-derived small RNAs and their application potential in multiple diseases.Frontiers in cell and developmental biology · 2022Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
26 authors at 14 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe 80-gene molecular subtyping signature (80-GS) reclassifies a proportion of immunohistochemistry (IHC)-defined luminal breast cancers (estrogen receptor-positive [ER+], human epidermal growth factor receptor 2-negative [HER2-]) as Basal-Type. We report the association of 80-GS reclassification with neoadjuvant treatment response and 5-year outcome in patients with breast cancer.
methodsNeoadjuvant Breast Registry Symphony Trial (NBRST; NCT01479101) is an observational, prospective study that included 1,069 patients with early-stage breast cancer age 18-90 years who received neoadjuvant therapy. Pathologic complete response (pCR) and 5-year distant metastasis-free survival (DMFS) and overall survival (OS) were assessed in 477 patients with IHC-defined ER+, HER2- tumors and in a reference group of 229 patients with IHC-defined triple-negative breast cancer (TNBC).
results80-GS reclassified 15% of ER+, HER2- tumors (n = 73) as Basal-Type (ER+/Basal), which had similar pCR compared with TNBC/Basal tumors (34%
conclusionSignificant differences in chemosensitivity and 5-year outcome suggest patients with ER+/Basal molecular subtype may benefit from neoadjuvant regimens optimized for patients with TNBC/Basal tumors compared with patients with ER+/Luminal subtype. These data highlight the importance of identifying this subset of patients to improve treatment planning and long-term survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.